Umicore SA (0RUY)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 18.04 |
|---|---|
| 52-week range | 14.21 – 26.96 |
| Return, 1 month / 3 months | −16.0% / −9.3% |
| Return, 1 year / 3 years | +5.3% / −13.6% |
| Trend | Below its 200-day average |
| RSI (14) | 22 |
| Volatility (1 year) | 48.6% |
| Worst drawdown (1 year) | -30.9% |
| Average daily value traded | 3.18M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Umicore is a materials technology and recycling company based in Belgium. It makes catalysts for vehicle emissions control, specialty materials and precious metal products, and it recovers metals from industrial residues and used materials at its recycling operations. Its customers include car makers, chemical producers, electronics manufacturers and other industrial firms that need advanced materials or metal recovery services. The company combines materials science with closed-loop metal recovery across its business lines.
On this site Umicore SA appears as a stock on the London Exchange (UK), code 0RUY, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Umicore SA (0RUY) trades on the London Exchange in UK. It last closed at EUR 18.04 on 22 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 2,223 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.3% and over the last three months it fell 9.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 41 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -12.0% | ||
| From 52-week high | -30.9% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -9.3% | ||
| 6-month return | 6.4% | ||
| 12-month return, skipping the last month | 25.4% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.9% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.18M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −12.3% |
|---|---|
| 1 month | −16.0% |
| 3 months | −9.3% |
| 6 months | +6.4% |
| 1 year | +5.3% |
| 3 years | −13.6% |
| 5 years | −60.1% |
Signals
| 50-day / 200-day average | 21.81 / 20.50 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.68 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Apr 2025 | EUR 0.1750 |
| 19 Aug 2024 | EUR 0.1750 |
| 29 Apr 2024 | EUR 0.3850 |
| 18 Aug 2023 | EUR 0.1750 |
| 2 May 2023 | EUR 0.3850 |
| 19 Aug 2022 | EUR 0.1750 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.